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Interventional Cardiology
DES Reduce Mortality Compared to BMS, Even When Used “Off-Label”
The indications approved by the Food and Drug Administration for drug-elutingstents (DES), based on the inclusion/exclusion criteria of randomized trials, only
include patients with a single de novo native coronary artery lesion30mm in length,
a left ventricular ejection fraction25%, and nomyocardial infarction (MI) within 7
days of the procedure. Applegate and colleagues compared outcomes in almost 3,000
patients with either bare-metal stent (BMS) or DES and stratified by whether or not
their use should be considered “off-label.” At 2 years, the hazard ratio for DES
compared to BMS for nonfatal MI or death was 0.77 for all patients. For “off-label”
stent procedures this hazard ratio was 0.78, and for all-cause mortality it was 0.72. In
this study, the use of DES for “off-label” indications was associated with similar
nonfatal MI and death at 2 years than in a comparable group of patients treated with
BMS. See page 607. See figure.
Interventional Cardiology
SES Superior to BMS for STEMI
VanderHoeven and colleagues randomized300 ST-segment elevationmyocar-dial infarction (STEMI) patients to either sirolimus-eluting stents (SES) or
bare-metal stents (BMS), with intravascular ultrasound follow-up at 9 months, and
clinical events follow-up 1 year. Late lumen loss and target vessel revascularizationwere
significantly reducedwith SES.However, late stentmalapposition (LSM), defined as a
separationof at least one stent strut from the intimal surfacewithbloodflowbehind the
strut, developed in 25% of SES patients versus only 5% of BMS patients. Rates of
death, myocardial infarction and stent thrombosis were not different. SES implanta-
tion in STEMI patients results in improved mid-term clinical and angiographic
outcomes compared to treatment with BMS; however, LSM raises concern about the
future risk of stent thrombosis. See page 618.
Page 640
Coronary Artery Disease
Large HDL Particles May Increase Cardiac Risk
Increased plasma high-density lipoprotein cholesterol (HDL-C) is generally associ-ated with decreased cardiac risk, but recent studies evaluating the effect of potent
HDL-C increases through torcetrapib did not demonstrate clinical benefit. van der
Steeg and colleagues therefore studied the relationship betweenHDL-C, high-density
lipoprotein (HDL) particle size and apolipoprotein A-I (apoA-I) concentrations and
cardiac events in two large datasets, with a particular focus on those subjects with very
high values of these parameters. When levels of apolipoprotein B and apoA-I were
adjusted for, very high values of HDL-C (70 mg/dl) and HDL particle size (9.5
nm)were associatedwith increased risk of coronary artery disease. These results suggest
that largeHDL particles increase cardiac risk, possibly by serving as cholesterol donors
rather than scavengers. See page 634. See figure.
(continued) A-26Preclinical Research
Early Versus Late Endothelial Progenitor Cells
The identity, origin, and function of endothelial progenitor cells (EPCs) remainsdebated. There appear to be two different times when EPCs appear in culture:
early EPCs and late-outgrowth endothelial cells (OECs). Early EPCs, which appear in
culture after 4 to 7 days, have been used for therapeutic studies. The OECs appear
much later in culture, after 14 to 21 days. Sieveking and colleagues developed an assay
to functionally characterize the angiogenic properties of these 2 cell types. The OECs
formed branched, interconnecting tubules, and responded appropriately to known
pro- and antiangiogenic agents. In contrast, early EPCs failed to independently form
tubules or incorporate into differentiated EC tubules. Nevertheless, early EPCs
augmented tubulogenesis via a paracrine mechanism. These results suggest that early
EPCs augment angiogenesis while late OECs directly participate in tubulogenesis.
See page 660.
